Adipotide vs HGH Fragment 176-191.

Adipotide (FTPP, also called prohibitin-targeting peptide-1) is an experimental chimeric peptidomimetic designed to destroy the blood supply of white fat rather than act as a hormone. It was developed by Kolonin, Arap and Pasqualini and colleagues as a proof-of-concept anti-obesity agent that targets the vasculature feeding adipose tissue. Adipotide has only ever been tested in animals; it has never completed human clinical trials and is not a medicine. It is discussed here strictly as a preclinical research compound.

HGH Fragment 176-191 is a synthetic peptide corresponding to the final 16 amino acids (residues 176 to 191) of the C-terminal region of human growth hormone. It derives from the observation that this domain appears to carry GH's fat-metabolizing (lipolytic) activity while lacking the growth-promoting and insulin-antagonizing actions of the whole hormone. It is closely related to, but distinct from, AOD-9604, a modified analog in which a tyrosine residue is added to the N-terminus (developed under the name Anti-Obesity Drug 9604). The plain 176-191 fragment itself is a research-only compound with almost no dedicated clinical data.

Adipotide links two functional parts: a homing peptide (sequence CKGGRAKDC) that binds prohibitin, a protein found in unusual abundance on the endothelial cells of white-fat blood vessels, and a pro-apoptotic sequence (a KLAKLAK-type domain) that triggers programmed cell death once internalized. By selectively killing the endothelial cells that supply fat depots, the peptide is intended to starve and shrink adipose tissue. This vascular-targeting approach is fundamentally different from appetite- or metabolism-based drugs like GLP-1 agonists. The concept was first demonstrated in rodents before testing in primates.

The proposed mechanism is stimulation of lipolysis, the breakdown of stored triglycerides, along with reduced fat synthesis in adipose tissue, reproducing the fat-reducing effect of GH's C-terminus without activating the GH receptor to raise IGF-1 or impair glucose handling. Work on the analog AOD-9604 implicated the beta-3-adrenergic pathway in this effect. The mechanism is characterized mainly in mouse and in vitro models, and how faithfully the unmodified 176-191 fragment reproduces it in humans is not established.

The original concept was shown in a mouse study by Kolonin and colleagues in Nature Medicine (2004), in which targeted ablation of adipose vasculature reduced fat mass. The most cited primate work, by Barnhart and colleagues in Science Translational Medicine (2011), treated spontaneously obese rhesus monkeys with adipotide for 28 days and reported roughly 7-15% body-weight loss along with reduced body fat on imaging and improved insulin resistance, while untreated controls were unchanged. These findings were promising but limited to small animal cohorts. Both studies share the constraints of early preclinical work: small numbers of animals, short exposure, no blinding comparable to a clinical trial, imaging and biochemical surrogates rather than clinical endpoints, and no follow-up long enough to show whether fat loss persists once treatment stops or whether ablated adipose vasculature regenerates. No completed, peer-reviewed human efficacy trials exist, and marketed or clinical human data are absent. All human-facing claims about adipotide therefore rest on animal data only. The gap is total rather than partial: there is no published human pharmacokinetic profile, no established human tolerated exposure, no efficacy signal in people, and no regulatory review of any human dataset. That places adipotide in a different category from approved obesity pharmacotherapy. Drugs such as semaglutide and tirzepatide reached approval through multi-thousand-participant randomised Phase 3 programs with blinded comparators, adjudicated safety events and, in semaglutide's case, dedicated cardiovascular outcome data, and their weight-loss estimates come from human trials rather than extrapolation from monkeys. Any comparison of adipotide's reported primate weight change with those human results is not a like-for-like comparison, and the current literature on adipotide is largely mechanistic and vascular-targeting research rather than obesity therapeutics. Nothing published to date establishes that the approach translates from rodents and monkeys to people at all.

Almost all supportive data come from the modified analog AOD-9604 rather than from 176-191 itself. Heffernan et al., in Endocrinology (2001, PMID 11713213), showed that AOD9604 reduced body weight and increased lipolysis in obese mice and that the effect disappeared in beta-3-adrenergic-receptor knockout mice, implicating that pathway. That was a rodent study using genetically obese and knockout strains, with short treatment periods and body-weight and tissue endpoints rather than clinical outcomes. Its central finding, dependence on a receptor whose contribution to human fat metabolism is far smaller than in rodents, is itself a reason to doubt direct translation. AOD-9604 was later carried into human obesity trials but did not produce clinically meaningful weight loss beyond placebo and was not approved as a drug. The program, run by an Australian sponsor, was discontinued after the larger placebo-controlled trial failed to separate from placebo on weight, which is the endpoint that matters for an anti-obesity indication. The compound was subsequently repositioned toward non-pharmaceutical uses, and a separate strand of published work examined intra-articular AOD9604 in a rabbit osteoarthritis model rather than obesity, which says nothing about systemic fat loss. For the unmodified 176-191 fragment specifically there is essentially no controlled human evidence, and its reputation is extrapolated from AOD-9604 data. The tyrosine added to the N-terminus of AOD-9604 was a deliberate stability modification, so the two molecules are not interchangeable, and no published head-to-head comparison establishes that the plain fragment behaves like the analog in people. The contrast with full-length somatropin is instructive: recombinant GH has approved indications, product labeling, decades of registry data, and a well-mapped metabolic profile, while the fragment has none of that. There are no human pharmacokinetic data for 176-191, no bioavailability data, no dose-ranging work, no imaging-based body-composition endpoints, and no long-term study of any kind.

The pivotal primate study identified dose-dependent renal toxicity, specifically renal tubular changes, as the main safety signal at doses that produced meaningful weight loss; these kidney effects were a major reason human development did not advance. That finding matters because it appeared at exposures tied to the desired effect rather than only at extreme excess, which is the pattern that most often halts a candidate before first-in-human work. Because adipotide has not been through human trials, its safety in people is unknown and unvalidated. No human dose has been shown to be tolerated, there is no characterised human adverse-event profile, no drug-interaction data, and no evidence about what monitoring would even detect harm early. A legitimate first-in-human program for a pro-apoptotic vascular-targeting agent of this kind would require intensive renal function monitoring, careful dose escalation with stopping rules, and independent safety oversight, none of which applies to informal use. Material sold online as research chemical is unregulated and not quality-controlled, meaning the identity, potency, purity, endotoxin content and sterility of the vial are unverified, and there is no manufacturer accountable for a bad batch or any channel for reporting injury. Adipotide is not approved for human use in any jurisdiction, and the combination of a known organ-toxicity signal in primates with an unregulated supply chain is the central safety consideration for this compound.

In its trials the analog AOD-9604 was generally well tolerated over short periods, with headache and mild edema among the reported effects, but the plain 176-191 fragment has no comparable human safety record of its own. Long-term safety is unknown. The theoretical selling point of the fragment, that it separates GH's lipolytic action from the growth-promoting and insulin-antagonizing actions of the whole hormone, has never been confirmed in a controlled human study, so the assumption that it avoids GH's metabolic liabilities remains an assumption rather than a finding. Full-length growth hormone reliably raises IGF-1 and can worsen glucose tolerance and cause fluid retention, carpal tunnel symptoms, and arthralgia. Whether a C-terminal fragment is genuinely free of those effects at meaningful exposure is untested, and no study has measured IGF-1 or glucose handling during sustained exposure to the fragment. Because the peptide is administered by injection, the usual injection risks apply: local reactions, infection from non-sterile technique or non-sterile product, and immune response to a foreign fragment. Nothing published characterizes immunogenicity for this sequence. Injectable material sold online as Fragment 176-191 is unregulated research-grade product of uncertain identity and purity, frequently supplied without a certificate of analysis or with one that cannot be traced to the vial in hand, and independent testing of this market has found mislabeled and contaminated product. A proper trial would require fasting glucose and insulin, IGF-1, and lipid monitoring, together with sterility and endotoxin testing of the material, none of which happens outside a regulated setting. The safety of the fragment itself remains largely uncharacterized.

Adipotide is a preclinical/research compound with no FDA, EMA, or other regulatory approval for any use. It is not an approved drug or supplement, and no legitimate human therapeutic product exists. Any human use would be unapproved and unstudied.

HGH Fragment 176-191 is not an approved drug and is sold as research-use-only. The related AOD-9604 was investigated for obesity, failed to reach approval as a pharmaceutical, and was subsequently pursued as a food and cosmetic ingredient in some markets; neither has FDA approval as a weight-loss medicine. GH fragments of this type are prohibited in sport by WADA.